Schisandrin B attenuates pressure overload‑induced cardiac remodeling in mice by inhibiting the MAPK signaling pathway

Ai,Fen; Guo,Qing‑Hao; Yu,Bo; Li,Wei; Guo,Xin; Chen,Zhen

doi:10.3892/etm.2019.8154

Schisandrin B attenuates pressure overload‑induced cardiac remodeling in mice by inhibiting the MAPK signaling pathway

Authors:
- Fen Ai
- Qing‑Hao Guo
- Bo Yu
- Wei Li
- Xin Guo
- Zhen Chen
View Affiliations

Affiliations: Department of Emergency, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China, Department of Cardiovascular Medicine, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, P.R. China
Published online on: October 31, 2019 https://doi.org/10.3892/etm.2019.8154
Pages: 4645-4652
Copyright: © Ai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the current study was to investigate the effect and mechanism of schisandrin B (Sch B) on myocardial hypertrophy induced by pressure overload in mice. Male C57BL/6J mice were randomly divided into three groups: i) Sham (n=12); ii) transverse aortic constriction (TAC) (n=12); and iii) Sch B‑treated (n=12; 80 mg·kg‑1·d‑1 per gavage). The model of myocardial hypertrophy was established by constricting the descending branch of the aortic arch. Following a 4‑week treatment period, cardiac remodeling was evaluated using echocardiography and pathological and molecular analysis. Sch B improved cardiac function in the Sch B‑treated group compared with the TAC group. Moreover, the Sch B‑treated group had a smaller myocardial cell cross‑sectional area and less fibrosis compared with the TAC group. The protein expression levels of cardiac hypertrophy and fibrosis markers in the TAC group were significantly higher compared with those in the sham group. The same markers in the Sch B‑treated group were significantly lower compared with those in the TAC group. Additionally, the phosphorylation levels of the mitogen‑activated protein kinase (MAPK) signaling pathway‑associated proteins extracellular signal‑regulated kinase 1/2, c‑Jun N‑terminal kinase 1/2 and P38 mitogen‑activated protein kinase were significantly lower in the Sch B‑treated group compared with the TAC group. Further in vitro investigation demonstrated that Sch B prevented the adverse effects of angiotensin II‑induced hypertrophy and fibrosis by inhibiting the MAPK signaling pathway in H9c2 cells. In conclusion, Sch B may improve pathological myocardial remodeling and cardiac function induced by pressure overload, and its underlying mechanism may be associated with inhibition of the MAPK signaling pathway.

View Figures

View References

1	Metra M and Teerlink JR: Heart failure. Lancet. 390:1981–1995. 2017. View Article : Google Scholar : PubMed/NCBI
2	Burchfield JS, Xie M and Hill JA: Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation. 128:388–400. 2013. View Article : Google Scholar : PubMed/NCBI
3	Opie LH, Commerford PJ, Gersh BJ and Pfeffer MA: Controversies in ventricular remodelling. Lancet. 367:356–367. 2006. View Article : Google Scholar : PubMed/NCBI
4	Drazner MH: The progression of hypertensive heart disease. Circulation. 123:327–334. 2011. View Article : Google Scholar : PubMed/NCBI
5	Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, et al: Animal models of heart failure: A scientific statement from the american heart association. Circ Res. 111:131–150. 2012. View Article : Google Scholar : PubMed/NCBI
6	Shimizu I and Minamino T: Physiological and pathological cardiac hypertrophy. J Mol Cell Cardiol. 97:245–262. 2016. View Article : Google Scholar : PubMed/NCBI
7	Heineke J and Molkentin JD: Regulation of cardiac hypertrophy by intracellular signalling pathways. Nature reviews. Nat Rev Mol Cell Biol. 7:589–600. 2006. View Article : Google Scholar : PubMed/NCBI
8	Tham YK, Bernardo BC, Ooi JY, Weeks KL and McMullen JR: Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets. Arch Toxicol. 89:1401–1438. 2015. View Article : Google Scholar : PubMed/NCBI
9	Panossian A and Wikman G: Pharmacology of schisandra chinensis bail: An overview of Russian research and uses in medicine. J Ethnopharmacol. 118:183–212. 2008. View Article : Google Scholar : PubMed/NCBI
10	Ip SP, Poon MK, Wu SS, Che CT, Ng KH, Kong YC and Ko KM: Effect of schisandrin B on hepatic glutathione antioxidant system in mice: Protection against carbon tetrachloride toxicity. Planta Med. 61:398–401. 1995. View Article : Google Scholar : PubMed/NCBI
11	Checker R, Patwardhan RS, Sharma D, Menon J, Thoh M, Bhilwade HN, Konishi T and Sandur SK: Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-κB. Free Radic Biol Med. 53:1421–1430. 2012. View Article : Google Scholar : PubMed/NCBI
12	Xu Y, Liu Z, Sun J, Pan Q, Sun F, Yan Z and Hu X: Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PLoS One. 6:e283352011. View Article : Google Scholar : PubMed/NCBI
13	Thandavarayan RA, Giridharan VV, Arumugam S, Suzuki K, Ko KM, Krishnamurthy P, Watanabe K and Konishi T: Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS One. 10:e01192142015. View Article : Google Scholar : PubMed/NCBI
14	Chen P, Pang S, Yang N, Meng H, Liu J, Zhou N, Zhang M, Xu Z, Gao W, Chen B, et al: Beneficial effects of schisandrin B on the cardiac function in mice model of myocardial infarction. PLoS One. 8:e794182013. View Article : Google Scholar : PubMed/NCBI
15	Chiu PY and Ko KM: Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Mol Cell Biochem. 266:139–144. 2004. View Article : Google Scholar : PubMed/NCBI
16	Zhang W, Sun Z and Meng F: Schisandrin B ameliorates myocardial ischemia/reperfusion injury through attenuation of endoplasmic reticulum stress-induced apoptosis. Inflammation. 40:1903–1911. 2017. View Article : Google Scholar : PubMed/NCBI
17	Liu Y, Jiang XL, Liu Y, Jiang DS, Zhang Y, Zhang R, Chen Y, Yang Q, Zhang XD, Fan GC and Li H: Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice. Cardiovasc Res. 101:87–96. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wang Z, You L, Cheng Y, Hu K, Wang Z, Cheng Y, Yang J, Yang Y and Wang G: Investigation of pharmacokinetics, tissue distribution and excretion of schisandrin B in rats by HPLC-MS/MS. Biomed Chromatogr. 32:2018.
19	Ko KM, Chen N, Leung HY, Leong EP, Poon MK and Chiu PY: Long-term schisandrin B treatment mitigates age-related impairments in mitochondrial antioxidant status and functional ability in various tissues, and improves the survival of aging C57BL/6J mice. Biofactors. 34:331–342. 2008. View Article : Google Scholar : PubMed/NCBI
20	Leong PK, Chiu PY and Ko KM: Prooxidant-induced glutathione antioxidant response in vitro and in vivo: A comparative study between schisandrin B and curcumin. Biol Pharm Bull. 35:464–472. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chiu PY and Ko KM: Schisandrin B-induced increase in cellular glutathione level and protection against oxidant injury are mediated by the enhancement of glutathione synthesis and regeneration in AML12 and H9c2 cells. Biofactors. 26:221–230. 2006. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Beetz N, Rommel C, Schnick T, Neumann E, Lother A, Monroy-Ordonez EB, Zeeb M, Preissl S, Gilsbach R, Melchior-Becker A, et al: Ablation of biglycan attenuates cardiac hypertrophy and fibrosis after left ventricular pressure overload. J Mol Cell Cardiol. 101:145–155. 2016. View Article : Google Scholar : PubMed/NCBI
24	Zhai M, Liu Z, Zhang B, Jing L, Li B, Li K, Chen X, Zhang M, Yu B, Ren K, et al: Melatonin protects against the pathological cardiac hypertrophy induced by transverse aortic constriction through activating PGC-1beta: In vivo and in vitro studies. J Pineal Res. 63:2017. View Article : Google Scholar
25	Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, et al: Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: Efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 117:2626–2636. 2008. View Article : Google Scholar : PubMed/NCBI
26	Urban ML, Manenti L and Vaglio A: Fibrosis-A common pathway to organ injury and failure. N Engl J Med. 373:95–96. 2015. View Article : Google Scholar : PubMed/NCBI
27	Chen Q, Zhang H, Cao Y, Li Y, Sun S, Zhang J and Zhang G: Schisandrin B attenuates CCl₄-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-β/Smad signaling pathways. Drug Des Devel Ther. 11:2179–2191. 2017. View Article : Google Scholar : PubMed/NCBI
28	Zhang D, Liu B, Cao B, Wei F, Yu X, Li GF, Chen H, Wei LQ and Wang PL: Synergistic protection of Schizandrin B and Glycyrrhizic acid against bleomycin-induced pulmonary fibrosis by inhibiting TGF-β1/Smad2 pathways and overexpression of NOX4. Int Immunopharmacol. 48:67–75. 2017. View Article : Google Scholar : PubMed/NCBI
29	Jin H, Wang Z, Gu Z, Wu J, Bai X, Shao Z, Miao J, Wang Q, Wang Q and Wang X: Schisandrin B attenuates epidural fibrosis in postlaminectomy rats by inhibiting proliferation and extracellular matrix production of fibroblasts. Phytother Res. 33:107–116. 2019. View Article : Google Scholar : PubMed/NCBI
30	Hunter JJ, Tanaka N, Rockman HA, Ross J Jr and Chien KR: Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem. 270:23173–23178. 1995. View Article : Google Scholar : PubMed/NCBI
31	Cowan KJ and Storey KB: Mitogen-activated protein kinases: New signaling pathways functioning in cellular responses to environmental stress. J Exp Biol. 206:1107–1115. 2003. View Article : Google Scholar : PubMed/NCBI
32	Ran J, Ma C, Xu K, Xu L, He Y, Moqbel SAA, Hu P, Jiang L, Chen W, Bao J, et al: Schisandrin B ameliorated chondrocytes inflammation and osteoarthritis via suppression of NF-κB and MAPK signal pathways. Drug Des Devel Ther. 12:1195–1204. 2018. View Article : Google Scholar : PubMed/NCBI
33	Park EJ, Chun JN, Kim SH, Kim CY, Lee HJ, Kim HK, Park JK, Lee SW, So I and Jeon JH: Schisandrin B suppresses TGFbeta1 signaling by inhibiting Smad2/3 and MAPK pathways. Biochem Pharmacol. 83:378–384. 2012. View Article : Google Scholar : PubMed/NCBI